This $139,428.00 firm fixed price purchase order was awarded by the Defense Health Agency (DHA) to Biotheranostics Inc., a self-certified small disadvantaged business. The contract is for the provision of Biotheranostics' proprietary Breast Cancer Index genomic diagnostic testing services to support cancer care for the DHA's beneficiary population. This contract award represents one of several prime federal awards, totaling over $700,000 between 2021-2023, that Biotheranostics has received...
The U.S. Defense Health Agency (DHA) has awarded a $139,428 firm fixed price purchase order to Biotheranostics Inc., a self-certified small disadvantaged business, to provide Breast Cancer Index testing services. This award, with a completion date of September 25, 2024, is not set aside and supports the DHA's efforts to enhance cancer care for veterans and service members through advanced molecular diagnostics that guide treatment planning. Biotheranostics, a division of Hologic, Inc., has...
This firm-fixed-price purchase order was awarded to Biotheranostics Inc., a self-certified small disadvantaged business and division of Hologic, Inc. The $51,350 contract provides cancer identification testing services to the Department of Veterans Affairs (VA). The work supports the VA's efforts to enhance cancer care for veterans through advanced molecular diagnostics that guide treatment planning. Biotheranostics specializes in genomic diagnostic testing, including its proprietary Breast...
This is a $256,599.00 firm fixed price purchase order awarded by the Department of Veterans Affairs' Veterans Integrated Service Network 17 to Biotheranostics Inc., a self-certified small disadvantaged business and division of Hologic, Inc. The contract is for the provision of the Breast Cancer Index (BCI) diagnostic test. The BCI test leverages genomic analysis to aid in cancer screening, diagnosis, and treatment planning. This award is not set aside and is one of several prime federal...
This federal contract award to Genomic Health, Inc. is for the provision of breast cancer testing services to the Defense Health Agency (DHA), a defense agency within the U.S. Department of Defense. The $125,000.00 Firm Fixed Price Blanket Purchase Agreement (BPA) contract does not utilize any set-aside designations and was awarded on September 21, 2016, with a completion date of September 20, 2017. Genomic Health, a subsidiary of Exact Sciences Corporation, specializes in genomic-based cancer...
This award is for a purchase order of $78,364.30 to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, to provide breast cancer testing services to the Defense Health Agency. The contract has a firm fixed price pricing type and a completion date of September 30, 2016. Genomic Health is a for-profit organization that specializes in providing genomic cancer testing services to the federal government, including the Department of Veterans Affairs, Department of Defense, Air Force,...
This is a firm fixed-price BPA call order awarded by the Department of Veterans Affairs (VA) to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation. The contract, valued at $3,453.96, is for the provision of express cancer testing services, specifically Oncotype DX assays, to support the VA's healthcare programs. Genomic Health, as a provider of genomic-based cancer diagnostic tests, has received numerous prime and subcontractor awards from various federal agencies, including the...
The Defense Health Agency awarded a firm fixed price Blanket Purchase Agreement (BPA) call to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, for the provision of diagnostic testing supplies for cancer treatment. The potential value of the contract is $150,000.00, with a completion date of September 7, 2022. The contract was not set aside for any specific business type. Genomic Health has a history of providing cancer testing services, including its Oncotype DX portfolio of...
This is a delivery order awarded to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, for the provision of Oncotype cancer testing services to the Defense Health Agency (DHA). The contract has a ceiling value of $124,588.79 and a period of performance from March 16, 2025, to March 15, 2026, with the testing to be performed at Nellis Air Force Base in Nevada. The contract is a firm fixed-price type and does not have a set-aside designation. Genomic Health, Inc. is a for-profit...
This contract was awarded by the Defense Health Agency to Genomic Health, Inc., a developer and manufacturer of genomic and diagnostic tests for cancer detection and treatment. The contract provides for medical laboratory testing and analysis services, including Genomic Health's Oncotype DX Breast and Oncotype DX Colon cancer tests. The contract was awarded as a Blanket Purchase Agreement (BPA) call on a Firm Fixed Price basis, with a potential value of $125,000.00. The contract does not utilize...